



IFW

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Docket Number:  
**12961/46102**

Application Number  
**10/766,263**

Filing date  
**January 27, 2004**

Examiner  
**Z.C. TUCKER**

Art Unit  
**1624**

Invention Title  
**NOVEL DERIVATIVES OF 3,3-  
DIPHENYLPROPYLAMINES**


Inventor(s)  
**MEESE, et al.**

Address to:

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: February 14, 2006


By:

  
Joseph A. Coppola (Reg. No. 38,413)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed unless otherwise noted.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: February 14, 2006

By:

  
Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)  
**CUSTOMER NO. 26646**



**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT  
Form PTO-1449**

ATTY. DOCKET NO.  
**12961/46102**

APPLICATION NO.  
**10/766,263**

APPLICANT  
**Z.C. TUCKER**

FILING DATE  
**January 27, 2004**

GROUP  
**1624**

**U. S. PATENT DOCUMENTS\***

EXAMINER INITIAL	PATENT/PUBLICATION NUMBER	PATENT/PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	2003/0152624	August 14, 2003	Aldrich et al.			
	2003/0158176	August 21, 2003	Richards et al.			
	2004/064821	April 1, 2004	Rousselle			
	3,216,841	July 19, 1966	Zenitz			
	6,310,248	October 30, 2001	Andersson et al.			
	6,566,537	May 20, 2003	Andersson et al.			
	6,689,916	February 10, 2004	Andersson et al.			

\*- copies of U.S. references are not enclosed

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	766,207	December 22, 1952	DE			YES	
	831,799	June 7, 1996	EP				
	872,233	April 14, 1997	EP				
	948,321	December 10, 1997	EP				NO
	957,073	May 12, 1998	EP				
	1,025,041	February 24, 1964	GB				
	WO 02/089773	November 14, 2002	PCT				
	WO 02/11702	February 14, 2002	PCT				
	WO 03/002059	January 9, 2003	PCT				
	WO 03/007918	January 30, 2003	PCT				
	WO 03/020241	March 13, 2003	PCT				
	WO 03/026564	April 3, 2003	PCT				
	WO 03/035599	May 1, 2003	PCT				
	WO 03/039464	May 15, 2003	PCT				
	WO 03/063834	August 7, 2003	PCT				
	WO 03/099268	December 4, 2003	PCT				NO
	WO 03/103637	December 18, 2003	PCT				
	WO 03/106421	December 24, 2003	PCT				
	WO 04/019892	March 11, 2004	PCT				
	WO 98/43942	October 8, 1998	PCT				
	WO 98/56359	December 17, 1998	PCT				NO
	WO 99/58478	November 18, 1999	PCT				

# OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Lipinski, et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings" Elsevier Advanced Drug Delivery Reviews Vol. 23, pp. 3-25, 1997
		Netzer, et al., "Screening lead compounds for QT interval prolongation" Drug Discovery Today Vol. 6, No. 2, pp.78-84, January 2001
		Nilvebrant & Sparf, "Differences between Binding Affinities of some Antimuscarinic Drugs in the parotid Gland and those in the Urinary Bladder and Ileum" Acta Pharmacol. et toxicol. Vol. 53, No. 4, pp. 304-313, October 1983
		Pharmacology/Toxicology Review from Application Number 21-518, Center for Drug Evaluation and Research, pp. 1-3.
		Roy, et al., "HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine" Circulation Vol. 94, No. 4, pp. 817-823, August 15, 1996

EXAM INER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	